Supriya lifescience Limited has announced the completion of tenure for two independent directors as part of its regulatory disclosure obligations. The pharmaceutical company informed stock exchanges about this significant board development on March 24, 2026.

Directors' Tenure Completion

The company disclosed that the five-year consecutive terms of Mr. Dinesh Navnitlal Modi (DIN: 00004556) and Mr. Dileep Kumar Jain (DIN: 00380311) as independent directors concluded on March 24, 2026. Both directors completed their statutory maximum tenure as independent directors under corporate governance norms.

The board members conveyed their sincere appreciation for the contributions made by these directors during their long-term association with the company.

Board Committee Reconstitution

Following the directors' tenure completion, the board reconstituted its key committees during its meeting held on February 09, 2026. The restructured committees ensure continued compliance with corporate governance requirements.

Audit Committee:

Nomination and Remuneration Committee:

Stakeholders' Relationship Committee:

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company secretary and compliance officer, Prachi Sathe, signed the disclosure document ensuring proper regulatory compliance.

This board transition represents a routine corporate governance process as independent directors complete their maximum permissible tenure, ensuring fresh perspectives and continued adherence to independence requirements in board composition.

Supriya Lifescience Limited has issued a postal ballot notice dated February 09, 2026, seeking shareholder approval for the appointment and re-appointment of independent directors. The company has proposed three special resolutions for consideration through remote e-voting, demonstrating its commitment to strengthening board governance and independence.

Director Appointment Proposals

The postal ballot notice outlines three key appointments that require shareholder approval through special resolutions:

All three directors will serve as Non-Executive Independent Directors for five consecutive years and will not be liable to retire by rotation. The Board of Directors appointed Mr. Panchal and Mr. Hari as Additional Directors on February 09, 2026, following recommendations from the Nomination and Remuneration Committee.

Voting Process and Timeline

The company has established a comprehensive e-voting framework in compliance with regulatory requirements. The remote e-voting period is scheduled as follows:

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facilities to shareholders. Only members whose names appear in the Register of Members or List of Beneficial Owners as on the cut-off date will be eligible to vote.

Director Profiles and Expertise

Mr. Manish Panchal brings over 32 years of cross-industry experience spanning chemicals, logistics, pharmaceuticals, medical devices, and healthcare sectors. His expertise includes strategy and innovation, operational excellence, business development, and P&L management. He holds advanced qualifications from prestigious institutions including Asian Institute of Management and Stanford University Graduate School of Business.

Mr. Kothandaraman Hari is a capital markets professional with over 28 years of experience, having contributed significantly to the National Stock Exchange of India's growth as Executive Vice President. He is a qualified Cost Accountant and Company Secretary, currently serving as founder of Onspin Consultants LLP.

Dr. Neelam Arora possesses over 31 years of teaching experience and 10 years of administrative experience in education. She holds advanced degrees including M.Com, L.L.M., and Ph.D., bringing valuable expertise in commerce, taxation, economics, and law to the board.

Regulatory Compliance

The postal ballot process adheres to multiple regulatory frameworks including Section 110 of the Companies Act, 2013, SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and various Ministry of Corporate Affairs circulars. All proposed directors have submitted declarations confirming their independence criteria and eligibility for appointment as Independent Directors.

The company will communicate results to BSE Limited and National Stock Exchange of India Limited, where its equity shares are listed, and make them available on the company website and NSDL's e-voting portal following the declaration.